JP2022505923A5 - - Google Patents
Info
- Publication number
- JP2022505923A5 JP2022505923A5 JP2021523009A JP2021523009A JP2022505923A5 JP 2022505923 A5 JP2022505923 A5 JP 2022505923A5 JP 2021523009 A JP2021523009 A JP 2021523009A JP 2021523009 A JP2021523009 A JP 2021523009A JP 2022505923 A5 JP2022505923 A5 JP 2022505923A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754378P | 2018-11-01 | 2018-11-01 | |
| US62/754,378 | 2018-11-01 | ||
| PCT/US2019/059556 WO2020093024A2 (en) | 2018-11-01 | 2019-11-01 | Methods of administering anti-tim-3 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505923A JP2022505923A (ja) | 2022-01-14 |
| JPWO2020093024A5 JPWO2020093024A5 (https=) | 2022-11-08 |
| JP2022505923A5 true JP2022505923A5 (https=) | 2022-11-08 |
Family
ID=69159932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523009A Pending JP2022505923A (ja) | 2018-11-01 | 2019-11-01 | 抗ｔｉｍ－３抗体を投与する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220073616A1 (https=) |
| EP (1) | EP3873612A2 (https=) |
| JP (1) | JP2022505923A (https=) |
| CN (1) | CN113301961A (https=) |
| AU (1) | AU2019372436A1 (https=) |
| CA (1) | CA3117371A1 (https=) |
| IL (1) | IL282708A (https=) |
| WO (1) | WO2020093024A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200231652A1 (en) | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| CN118255902A (zh) | 2017-03-02 | 2024-06-28 | 加拿大国家研究委员会 | TGF-β受体胞外域融合分子及其用途 |
| MX2023000005A (es) * | 2020-06-26 | 2023-03-06 | Sorrento Therapeutics Inc | Virus del herpes simple (vhs) oncolíticos que expresan proteínas de fusión inmunomoduladoras. |
| CN117120091A (zh) * | 2021-04-13 | 2023-11-24 | 免疫医疗有限责任公司 | 靶向pd-1和tim-3的双特异性抗体 |
| CN117377692A (zh) | 2021-04-23 | 2024-01-09 | 苏州逻晟生物医药有限公司 | Tim-3-靶向抗体及其用途 |
| CN117545506A (zh) * | 2021-06-24 | 2024-02-09 | 百时美施贵宝公司 | 用于治疗疾病的转化生长因子-β配体陷阱 |
| CN116688115B (zh) * | 2022-03-18 | 2024-02-06 | 上海齐鲁制药研究中心有限公司 | 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| AU2002248571B2 (en) | 2001-03-07 | 2007-01-18 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| US7919092B2 (en) * | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
| CA3083324A1 (en) | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US8841418B2 (en) * | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| EP3099717B1 (en) * | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| US9676863B2 (en) * | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| MX370807B (es) * | 2014-07-11 | 2020-01-08 | Genmab As | Anticuerpos que se unen a axl. |
| TWI716362B (zh) * | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| EP3878465A1 (en) * | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| CN109414500B (zh) * | 2016-06-13 | 2022-02-25 | 奥美药业有限公司 | 治疗和诊断用pd-l1特异性单克隆抗体 |
| CN109640988A (zh) * | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| JOP20190013A1 (ar) * | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| SG11201903867YA (en) * | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| EA201990743A1 (ru) * | 2016-11-29 | 2019-11-29 | Антитела, направленные против белка-3, содержащего т-клеточный иммуноглобулин и муцин (tim-3) | |
| AU2018264455B2 (en) | 2017-05-12 | 2024-12-12 | Jiangsu Hengrui Medicine Co., Ltd. | Fusion protein containing TGF-beta receptor and medicinal uses thereof |
-
2019
- 2019-11-01 EP EP19835890.5A patent/EP3873612A2/en not_active Withdrawn
- 2019-11-01 CA CA3117371A patent/CA3117371A1/en active Pending
- 2019-11-01 WO PCT/US2019/059556 patent/WO2020093024A2/en not_active Ceased
- 2019-11-01 AU AU2019372436A patent/AU2019372436A1/en not_active Abandoned
- 2019-11-01 CN CN201980086650.3A patent/CN113301961A/zh active Pending
- 2019-11-01 JP JP2021523009A patent/JP2022505923A/ja active Pending
-
2021
- 2021-04-27 IL IL282708A patent/IL282708A/en unknown
- 2021-04-30 US US17/245,476 patent/US20220073616A1/en not_active Abandoned